Equity Profile

RGC

Regencell Bioscience Holdings Limited

Health CarePharmaceuticals$9.9B

Jun27Thu

Pre-Earnings Brief

UpcomingQ4-2017After Close5:00 PM EDT

Company Snapshot

Regencell Bioscience Holdings Limited is a pharmaceutical company focused on developing innovative treatments in the health care sector. With a market cap of $12 billion, it plays a significant role in addressing health challenges through its research and product offerings.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and is closely watched by investors.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and increase sales.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RGC Q4-2017 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-3.97%

Avg Stock Reaction

+0.00%

Last Quarter Recap

In the last quarter, Regencell reported an EPS of $0.07, which was below the expected $0.11, resulting in a 36% negative surprise. The stock reaction was muted, indicating investor caution.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Regencell's upcoming earnings are mixed, given the recent history of EPS misses. Investors are looking for signs of improvement in profitability and revenue.

Bull Case

The optimistic view is that Regencell could surprise the market with better-than-expected EPS and revenue growth, indicating a turnaround in performance.

Bear Case

On the downside, if the company continues to miss EPS estimates, it may raise concerns about its operational efficiency and future growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Regencell's EPS exceed $0.07 this quarter?

Given the company's recent history of misses, a positive EPS could signal a turnaround and boost investor confidence.

What are the revenue figures for this quarter?

Revenue growth is crucial for assessing the company's market performance and future potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Regencell's potential for recovery, as recent product developments could lead to better-than-expected results.

Supporting Evidence

The options market is pricing a significant move, indicating that investors are anticipating volatility.

Historical EPS misses may not fully account for recent operational improvements.

The company's market cap suggests that even small positive surprises could lead to a substantial stock price increase.

Key Risk

If EPS comes in above $0.10, it could shift the narrative significantly and challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will determine whether Regencell can regain investor confidence after recent misses.

Bull Confirmed If

An EPS of $0.10 or higher would confirm the bull case and indicate improved profitability.

Bear Confirmed If

An EPS below $0.05 would confirm the bear case and raise concerns about the company's operational effectiveness.

Pre-Earnings Positioning

Options Market

Implied Move

±11.9%

The options market is pricing in a significant move around the earnings report, suggesting that investors expect volatility.

Detail

ATM IV

1.4%

30d HV

69.6%

Calls (5K)P/C Ratio: 0.02Puts (7K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Regencell beats expectations, history suggests the stock could rise by an average of 3.6%, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.

Miss

If the company misses again, history indicates a potential decline of around 1.3%, reflecting ongoing investor concerns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline developments.
2Specific revenue figures and growth rates.
3Management's outlook on future earnings.
4Comments on operational efficiencies and cost management.
5Insights into market conditions affecting sales.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jun25

SNXReported

TD SYNNEX Corporation

RecapView

Jun25

CUKReported

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and is closely watched by investors.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and increase sales.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RGC Q4-2017 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-3.97%

Avg Stock Reaction

+0.00%

Last Quarter Recap

In the last quarter, Regencell reported an EPS of $0.07, which was below the expected $0.11, resulting in a 36% negative surprise. The stock reaction was muted, indicating investor caution.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Regencell's upcoming earnings are mixed, given the recent history of EPS misses. Investors are looking for signs of improvement in profitability and revenue.

Bull Case

The optimistic view is that Regencell could surprise the market with better-than-expected EPS and revenue growth, indicating a turnaround in performance.

Bear Case

On the downside, if the company continues to miss EPS estimates, it may raise concerns about its operational efficiency and future growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Regencell's EPS exceed $0.07 this quarter?

Given the company's recent history of misses, a positive EPS could signal a turnaround and boost investor confidence.

What are the revenue figures for this quarter?

Revenue growth is crucial for assessing the company's market performance and future potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Regencell's potential for recovery, as recent product developments could lead to better-than-expected results.

Supporting Evidence

The options market is pricing a significant move, indicating that investors are anticipating volatility.

Historical EPS misses may not fully account for recent operational improvements.

The company's market cap suggests that even small positive surprises could lead to a substantial stock price increase.

Key Risk

If EPS comes in above $0.10, it could shift the narrative significantly and challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will determine whether Regencell can regain investor confidence after recent misses.

Bull Confirmed If

An EPS of $0.10 or higher would confirm the bull case and indicate improved profitability.

Bear Confirmed If

An EPS below $0.05 would confirm the bear case and raise concerns about the company's operational effectiveness.

Pre-Earnings Positioning

Options Market

Implied Move

±11.9%

The options market is pricing in a significant move around the earnings report, suggesting that investors expect volatility.

Detail

ATM IV

1.4%

30d HV

69.6%

Calls (5K)P/C Ratio: 0.02Puts (7K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Regencell beats expectations, history suggests the stock could rise by an average of 3.6%, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.

Miss

If the company misses again, history indicates a potential decline of around 1.3%, reflecting ongoing investor concerns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline developments.
2Specific revenue figures and growth rates.
3Management's outlook on future earnings.
4Comments on operational efficiencies and cost management.
5Insights into market conditions affecting sales.